If the group wants to pivot from meta‑refinement to concrete trial design, here’s a concise, prioritized checklist and set of practical decisions to pre‑register for a trial testing whether a defined microbiome intervention (e.g., butyrate‑producing consortium) affects depressive symptoms via fecal butyrate change. Primary design decisions (pre‑specify exactly) - Primary clinical estimand: ITT difference in mean HAM‑D at 12 weeks (ANCOVA adjusting for baseline HAM‑D). Define handling of intercurrent events (treatment discontinuation, rescue meds) using treatment policy vs hypothetical strategy. - Primary mediation estimand: natural indirect effect (ACME) for change in fecal butyrate from baseline → week 4 on HAM‑D at 12 weeks (counterfactual mediation framework). State scale (raw vs standardized). Declare this as secondary if total effect is primary. - Single primary mediator and timepoint: fecal butyrate change baseline→week 4 (justify biologically and with pilot kinetics). All other mediators are exploratory and clearly labeled. Mediator measurement (operationalize in SOP) - Stool collection SOP: timing relative to dose, kit (stabilizer or immediate freezing), instructions, cold‑chain, storage time limits. - Assay method: specify platform (e.g., targeted GC‑MS or LC‑MS for SCFAs), lab, LOD/LOQ, calibration, internal standards. Pre‑register normalization (e.g., per gram wet weight, or per dry weight) and handling of values below LOD. - Replicates / reliability: include a subsample (≥10–20%) with duplicate collection or split aliquots to estimate measurement error (ICC). Use these to correct attenuation if needed. Temporal ordering and rationale - Justify mediator timepoint as early enough to plausibly lie on the causal path (week 4) and before outcome measurement (week 12). If pharmacodynamics are uncertain, run a small pilot to confirm mediator kinetics. Identification assumptions and covariates - State identification assumptions explicitly: randomization removes treatment→(confounder) bias; assume no unmeasured mediator→outcome confounding conditional on pre‑treatment covariates. List and pre‑register covariates to adjust for (baseline HAM‑D, age, sex, BMI, baseline fiber intake, baseline butyrate). - If strong mediator–outcome confounding is plausible (diet, antibiotics, concomitant meds), collect those measures and include them in the mediator and outcome models. Analysis plan (pre‑specify models and estimators) - Mediator model: specify functional form (e.g., linear regression for continuous butyrate change) and covariates. - Outcome model: ANCOVA for HAM‑D with treatment, mediator, covariates. State whether parametric assumptions will be checked and an alternative (e.g., robust/bootstrapped SEs) used if violated. - Mediation estimator: name the method (Imai’s mediation package / g‑formula / inverse‑odds weighting) and the software/version. Pre‑specify bootstrap CI procedure and number of resamples. - Moderation (if included): pre‑specify a single moderator, treat continuously if possible, state interaction term(s), and pre‑specify the interpretation and plots (e.g., mod effect at specific percentiles). Power and sample size - Primary: power the trial for the clinical total effect (primary outcome). - Mediation: explicitly simulate mediation power under plausible mediator variances and path coefficients (a and b paths). State that mediation detection typically requires larger N than total effect; provide simulation code and scenarios in the registry. - Practical guidance: unless pilot data suggest large indirect effects, plan for several hundred participants for reliable mediation inference; provide explicit simulation‑derived N for assumed effect sizes. Missing data and measurement error - Missing data: pre‑specify primary approach (multiple imputation under MAR with chained equations, include all variables predictive of missingness) and sensitivity analyses (pattern‑mixture or tipping point). - Measurement error: if reliability is moderate, pre‑specify correction (e.g., regression calibration or structural equation model) using replicate subsample. Sensitivity analyses (must pre‑register) - Mediation sensitivity: report sensitivity of ACME to unmeasured mediator–outcome confounding (e.g., Imai’s rho or VanderWeele’s bias formulas / E‑value for indirect effect). - Alternative mediators/timepoints: pre‑define a small set of exploratory mediators and timepoints and label them exploratory; control multiplicity via hierarchical ordering. - Compositional data: for microbiome‑relative abundance data used in secondary analyses, pre‑specify compositional transforms (clr/ilr) and robust methods. Feasibility and operational checks (run before full RCT) - Pilot study: estimate variance of mediator and outcome, assay CV, participant adherence to stool collection, and baseline distribution of moderators (diet). Use pilot data to finalize mediator timepoint and inform simulations. - Logistics: verify lab throughput, sample stability under expected shipping conditions, and per‑sample cost to ensure budget realism. Pre‑registration checklist items (to include verbatim in registry) - Primary and secondary estimands and hierarchy. - Complete mediator SOP and assay details. - Exact statistical models, estimators, and software versions. - Power simulation code and assumed parameter values. - Missing data strategy and sensitivity analyses. - Data sharing and analysis code release timeline. Miscellaneous practical points - Avoid post‑hoc dichotomization of moderators — pre‑specify continuous modeling or justified cutpoints. - Consider negative controls (e.g., measure an unrelated metabolite) to probe residual confounding. - If claiming mechanism, ensure language in registry distinguishes evidence strength (e.g., “consistent with mediation” vs “proves mediation”). If the group wants, I can: (A) draft a one‑page registry template with fields filled for the butyrate RCT, (B) sketch a simple simulation script outline for mediation power calculations, or (C) convert this checklist into a bullet checklist suitable for copying into ClinicalTrials.gov. Which of those is most useful?